Reverse T3: What This Test Actually Measures

What Reverse T3 Is and How It Forms

Reverse T3 is a structural mirror image of active T3. Both molecules contain three iodine atoms attached to a thyronine backbone, but the iodine atoms sit on different ring positions. That positional difference means rT3 cannot activate thyroid hormone receptors. It is metabolically inert.

The thyroid gland secretes mostly T4 (thyroxine). Peripheral tissues then remove one iodine atom via deiodinase enzymes. Type 1 deiodinase (DIO1) and type 2 deiodinase (DIO2) remove the iodine from the outer ring, producing bioactive T3. Type 3 deiodinase (DIO3) removes the iodine from the inner ring instead, producing rT3 [1].

Under normal conditions, roughly 40% of daily T4 converts to T3, and about 20% converts to rT3 [2]. The remainder is sulfated or glucuronidated and excreted.

The Deiodinase Switch

DIO3 expression increases sharply during physiologic stress. Cytokines including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) upregulate DIO3 in liver and skeletal muscle. The result is a shift in the T4 conversion ratio: more rT3, less active T3 [3].

This shift is thought to be adaptive. Reducing cellular metabolism during acute illness conserves energy. The clinical problem arises when the same shift persists during chronic low-grade stress, prolonged caloric restriction, or cortisol excess, all without an acute illness to justify it.

Receptor Competition

RT3 binds to thyroid hormone receptor beta (TRbeta) with measurable affinity, though it does not activate the receptor. At high concentrations, rT3 may competitively displace T3 from its receptor, blunting thyroid signaling even when free T3 is technically within the normal range [4]. Whether this competitive inhibition is clinically meaningful at the concentrations seen in ambulatory patients is still debated, but the mechanism is biochemically established.

Normal Reverse T3 Range

Most reference laboratories report an rT3 normal range of 9.2 to 24.1 ng/dL, though values vary slightly by assay platform. Quest Diagnostics uses 9.2 to 24.1 ng/dL; LabCorp reports 9.0 to 27.0 ng/dL using radioimmunoassay.

Why the Range Matters Less Than the Ratio

A single rT3 value interpreted in isolation is not very useful. An rT3 of 22 ng/dL is within range, but if free T3 has simultaneously fallen to 2.1 pg/mL, tissue thyroid signaling may be impaired even though neither value is technically abnormal. The free T3-to-rT3 ratio captures this relationship. Calculate it by dividing free T3 in pg/mL by rT3 in ng/dL. A ratio above 0.20 is generally considered adequate; values below 0.20 suggest that rT3 is disproportionately high relative to active T3 [5].

Age and Sex Adjustments

Published data show that rT3 tends to rise with age, independent of illness. A 2019 cross-sectional study of 1,687 euthyroid adults found that rT3 increased approximately 1.2 ng/dL per decade after age 40 [6]. Sex-based differences are small and not clinically significant enough to alter reference intervals in most laboratory protocols.

What High Reverse T3 Means

An rT3 above 24 to 27 ng/dL (depending on laboratory) signals excess T4 diversion away from active T3. This pattern is called "low T3 syndrome," "euthyroid sick syndrome," or "nonthyroidal illness syndrome" (NTIS) in the critical-care literature [7].

Causes of Elevated rT3

Critical illness. Sepsis, major surgery, burns, and trauma reliably raise rT3 within 24 to 48 hours of onset. In a study of 87 ICU patients, rT3 correlated inversely with APACHE II score and predicted 30-day mortality independently of TSH (P<0.001) [8].

Caloric restriction. Fasting as brief as 48 hours raises rT3 measurably. Prolonged very-low-calorie diets (below approximately 800 kcal/day) sustain elevated rT3 for weeks after caloric restriction ends, which may partly explain the metabolic adaptation seen in patients after bariatric surgery or aggressive weight-loss dieting [9].

Cortisol excess. Endogenous hypercortisolism (Cushing syndrome) and pharmacologic glucocorticoids both upregulate DIO3 and suppress DIO1, driving rT3 up. Dexamethasone 2 mg/day for five days raises rT3 by approximately 30% in healthy volunteers [10].

Medications. Amiodarone is the most clinically significant drug offender. It contains approximately 37% iodine by weight and inhibits both DIO1 and DIO3, but net rT3 usually rises because the drug impairs T4 clearance more than it promotes rT3 degradation [11]. Propranolol at doses above 160 mg/day also raises rT3 modestly by inhibiting peripheral T4-to-T3 conversion.

Selenium deficiency. DIO1 and DIO2 are selenoproteins. Selenium deficiency impairs the enzymes that convert T4 to active T3, so the DIO3 pathway receives a disproportionate share of T4 substrate, raising rT3. This mechanism is well-documented in regions with selenium-poor soil and in patients on long-term total parenteral nutrition [12].

Symptoms Associated With High rT3

No symptom is specific to elevated rT3. Patients often report fatigue, cold intolerance, difficulty losing weight, brain fog, and constipation. These overlap completely with hypothyroidism, which is why some clinicians argue that measuring rT3 adds diagnostic value when TSH is normal but symptoms persist. However, the Endocrine Society and AACE have not endorsed rT3 as a routine diagnostic test because outcome data from rT3-guided treatment protocols remain limited [13].

What Low Reverse T3 Means

An rT3 below 9.0 to 9.2 ng/dL is uncommon in ambulatory practice. It can occur in hyperthyroidism, where the gland overproduces T4 and T3 simultaneously and DIO3 cannot keep pace with substrate load. Low rT3 may also appear during T3-only thyroid hormone replacement, because exogenous T3 suppresses TSH and therefore reduces T4 production, leaving little T4 substrate for DIO3 to convert to rT3 [14].

Low rT3 is rarely the primary clinical concern. Its main practical relevance is as a confirmatory finding: a suppressed rT3 alongside elevated free T3 and suppressed TSH supports a diagnosis of overt hyperthyroidism or T3 toxicosis.

How to Lower Reverse T3

Reducing rT3 requires identifying and correcting the upstream driver. There is no drug approved specifically to lower rT3. Approaches are cause-specific.

Address the Underlying Stressor

If elevated rT3 is driven by critical illness, it typically normalizes within two to six weeks of clinical recovery without intervention [7]. Attempts to treat NTIS with exogenous T4 or T3 during active critical illness have not improved outcomes. The THYROTROPIN trial and a 2019 Cochrane review of thyroid hormone supplementation in critically ill patients found no mortality benefit from T3 or T4 replacement in NTIS [15].

Optimize Caloric Intake

For patients whose rT3 is elevated because of prolonged caloric restriction, restoring adequate protein and total caloric intake is the primary intervention. Research on 14 obese adults undergoing a 500 kcal/day deficit showed rT3 normalization within four weeks of returning to eucaloric feeding, with concurrent free T3 recovery [9].

Correct Selenium Deficiency

Supplementing selenium in deficient patients restores DIO1 and DIO2 activity. A randomized trial of 65 selenium-deficient adults found that 200 mcg/day of selenomethionine for 12 weeks reduced rT3 by 18% and increased the free T3-to-rT3 ratio from 0.17 to 0.24 (P<0.05) [12].

Review Medications

Stopping or reducing amiodarone rarely normalizes rT3 quickly because the drug has a half-life of 40 to 55 days. Switching from a non-selective beta-blocker to a selective agent (e.g., metoprolol) may reduce the rT3-elevating effect when rate control is still needed. Always discuss medication changes with the prescribing physician before altering doses.

How to Raise Reverse T3 (and Why You Usually Should Not Try)

Raising rT3 is not a clinical goal. The question arises from a misunderstanding: some patients, after reading that low rT3 is a "good sign," ask whether artificially keeping rT3 low is beneficial. The answer is that rT3 is a byproduct of normal T4 metabolism. Suppressing it pharmacologically while leaving the underlying regulatory system intact is not possible without altering the entire thyroid axis.

If rT3 is genuinely low due to overt hyperthyroidism, treatment with methimazole, propylthiouracil, or radioactive iodine normalizes T4 production and consequently normalizes rT3 as a secondary effect.

Ordering and Interpreting the Test

When to Order rT3

The AACE 2022 thyroid guidelines state that rT3 measurement "is not recommended as part of routine thyroid function testing" [13]. Ordering is most defensible in these specific situations:

• A patient has persistent hypothyroid symptoms with TSH and free T4 in the normal range and free T3 at the low end of normal.
• A patient is on T4 monotherapy (levothyroxine) and remains symptomatic despite normal TSH.
• A clinician wants to confirm that an ICU patient's low T3 is NTIS rather than primary central hypothyroidism.
• A patient has known risk factors for selenium deficiency or prolonged caloric restriction.

Interpreting Results in Context

Interpret rT3 alongside free T3, free T4, and TSH. A stepwise interpretation framework:

1. Is TSH suppressed or elevated? If so, treat the primary thyroid disorder first; rT3 is secondary.
2. Is free T3 low-normal or below range? If yes and rT3 is above 15 ng/dL, calculate the free T3-to-rT3 ratio.
3. Is the ratio below 0.20? If yes, identify a driver: illness, cortisol excess, caloric restriction, selenium deficiency, or relevant medications.
4. Retest after correcting the identified driver. An eight-to-twelve-week recheck is usually adequate given rT3's short plasma half-life and the slower normalization of underlying drivers.

Assay Variability

RT3 is measured by radioimmunoassay or liquid chromatography-tandem mass spectrometry (LC-MS/MS). LC-MS/MS is more specific because it does not cross-react with T3 sulfate or other thyronine metabolites. If a result seems inconsistent with the clinical picture, request a repeat using LC-MS/MS and confirm the laboratory's reference range applies to the assay method used [16].

Reverse T3 in Special Populations

Patients on Levothyroxine Monotherapy

About 10 to 15% of patients on levothyroxine report persistent symptoms despite normal TSH. One proposed explanation is that exogenous T4, when given as a single daily dose, generates a transient spike in T4 substrate available to DIO3, disproportionately raising rT3 in the hours after the dose. The Bianco and Kim review published in JAMA (2020) noted that "some patients treated with levothyroxine alone continue to report impaired quality of life, raising the question of whether T3 measurement and combination therapy deserve further study" [17]. RT3 measurement in this group may help identify patients whose free T3-to-rT3 ratio is persistently below 0.20 despite TSH normalization.

Pregnancy

RT3 rises modestly in the third trimester due to increased placental DIO3 expression [18]. Reference ranges used outside pregnancy do not apply after approximately 28 weeks of gestation. Clinicians should use trimester-specific thyroid reference ranges from the American Thyroid Association 2017 guidelines when interpreting any thyroid panel in pregnant patients.

Obesity and Metabolic Syndrome

Adipose tissue expresses DIO3. Higher fat mass correlates with higher rT3 independent of TSH, free T4, and free T3. A cross-sectional study of 312 adults with metabolic syndrome found mean rT3 of 19.4 ng/dL versus 13.8 ng/dL in age-matched controls without metabolic syndrome (P<0.001) [19]. This relationship complicates interpretation in patients with obesity: an elevated rT3 may reflect adipose DIO3 activity rather than illness or caloric restriction.

Reverse T3 and T3 Replacement Therapy

Some functional medicine and integrative endocrinology practitioners add liothyronine (T3) or prescribe desiccated thyroid extract (DTE) when rT3 is elevated and the free T3-to-rT3 ratio is low. The rationale is that exogenous T3 bypasses the DIO3 conversion step entirely. T3 does not convert to rT3; only T4 does.

The evidence base for this approach is narrow. A 2019 randomized trial by Idrees et al. Compared levothyroxine monotherapy with levothyroxine-plus-liothyronine combination therapy in 153 hypothyroid patients with persistent symptoms [20]. Combination therapy improved fatigue and depression scores on the ThyPRO questionnaire at 52 weeks versus monotherapy (P=0.03), though rT3 was not the selection criterion used in that trial. No large randomized trial has enrolled patients specifically on the basis of elevated rT3 or a depressed free T3-to-rT3 ratio as entry criteria. That evidence gap is the main reason AACE and the Endocrine Society have not formally endorsed rT3-guided T3 prescribing.

Patients considering combination therapy should understand that liothyronine has a four-to-six-hour plasma half-life, that twice-daily dosing is generally preferred to minimize peaks, and that starting doses typically range from 5 to 10 mcg twice daily with titration guided by free T3 and symptom response rather than rT3 alone.